-
Blog
Biomarker Assays in Drug Development: Choosing the Right Platform
[…] An assay that works for 10 samples in a discovery lab must be reproducible across hundreds or thousands of samples in a global clinical trial. Establishing a fit-for-purpose validation framework ensures that the assay rigor is proportional to the risk at the development phase, preventing over-engineering in early stages of the process. Comparing Biomarker […]
-
Blog
Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
[…] strengths and limitations, making it essential to choose the method that best fits the specific needs of the research or clinical application. Development and Validation of “ Fit-for-Purpose” Methodology Biomarkers serve various purposes in drug development, from exploratory hypothesis generation and internal decision-making to critical clinical decisions. U.S. regulatory authorities suggest a “fit-for-purpose” approach […]
-
Sitemap
Sitemap
[…] Activity Microsymposium on RNA Biology Modernizing Safety: The Predictive Power of In Vitro Toxicology Moving From GLP-1 to Multi-Target Metabolic Medicines mRNA Analytical Services: What Makes Testing Fit-for-Purpose mRNA Drugs: Progress, Production, and Prospects mRNA Vaccines and Therapeutics Conference mRNA-Based Therapeutics Bioanalysis mTOR Inhibition Enhances Targeted Protein Degradation Efficacy Munich Lab Automation Community (MLabAC) […]
-
Blog
Large Molecule Bioanalysis: Methods, Challenges & Best Practices
[…] rather than during formal validation. Plan immunogenicity assessment alongside pharmacokinetics: Integrate early anti-drug antibody testing to understand how immune responses affect systemic exposure and therapeutic efficacy. Develop fit-for-purpose methods before formal validation: Ensure that analytical rigor scales appropriately with the development stage, utilizing fit-for-purpose validation for exploratory work and fully validated assays for regulatory […]
-
Blog
Biomarker Assays: Designing Assays That Scale from Preclinical to Clinic
[…] context as the primary focus. Core Design Considerations for Scalable Clinical Biomarker Assays Successful scaling requires a translational biomarker strategy that anticipates developmental needs. This involves implementing fit-for-purpose biomarker assays that become more rigorous as a program moves from the early exploratory phase to later trials. Selecting the right analytical platform is an important decision. For […]
-
Blog
How Biomarker Testing Services Support Precision Medicine Programs
[…] medicine, biomarker testing services must offer a suite of technical capabilities that translate raw biological data into actionable insights. Biomarker assay development: Effective preclinical biomarker analysis requires fit-for-purpose design. This involves selecting the appropriate matrix – like serum, plasma, or tissue – and optimizing the assay for the necessary sensitivity and selectivity based on […]
-
Service
Biomarkers
[…] while preparing methods for greater rigor when regulatory or clinical use requires it. Assay Development and Validation Biomarker identification and feasibility assessment Assay development, optimization, and characterization Fit-for-purpose qualification for exploratory and translational studies Bioanalytical validation aligned with study and regulatory expectations Cross-species and matrix bridging from preclinical to clinical development Method transfer, sample […]
-
Blog
From screening to IND submission: Biomarker analysis in preclinical drug development
[…] after exposure to a medical product. For an accurate picture, it’s critical to establish that biomarkers and the test methods used to assess them are fit-for-purpose. A fit-for-purpose biomarker assay is “a conclusion that the level of validation associated with a medical product development assay is sufficient to support its context of use.” Full validation – […]
-
Blog
Preclinical vs. Clinical Biomarkers: Differences That Matter
[…] rework. Utilizing integrated biomarker services early in the design phase ensures that preclinical data improves the likelihood that early biomarker data remains relevant for downstream clinical milestones. Fit-for-Purpose vs. Validated Assays: The Core Technical Divide The most significant operational difference between development stages lies in the rigor of the analytical methods. Preclinical research usually […]
-
Blog
Alzheimer’s Disease Biomarkers: Toward More Precise Testing
[…] A Strategic Approach to AD Biomarker Testing As AD research moves toward earlier intervention and more targeted therapies, biomarker testing strategies must become more precise, standardized, and fit-for-purpose. A strong biomarker plan should consider not only which markers to measure, but also when to measure them, which sample type to use, which platform is […]